Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Huang, Zhiquan ^a   Tan, Ning ^b   Guo, Weijie ^c   Wang, Lili ^a   Li, Haigang ^a   Zhang, Tianyu ^b   Liu, Xiaojia ^b   Xu, Qin ^b   Li, Jinsong ^a   Guo, Zhongmin ^d  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CD147 ANTIGEN; EMMPRIN 2; GELATINASE A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE; BSG PROTEIN, HUMAN; ISOPROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN ISOFORMS; TUMOR CELLS, CULTURED; UP-REGULATION; YOUNG ADULT;

EID: 84899462841     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091596     Document Type: Article

References (47)

1. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154.
2. Hunter KD, Parkinson EK, Harrison PR (2005) Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135. (Pubitemid 40220338)
3. Galanski M (2006) Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 1: 285-295.
4. Colevas AD (2006) Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2644-2652.
5. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 7: 252-261.
6. Toole BP (2003) Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 54: 371-389.
7. Igakura T, Kadomatsu K, Taguchi O, Muramatsu H, Kaname T, et al. (1996) Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. Biochem Biophys Res Commun 224: 33-36. (Pubitemid 26252407)
8. Kuno N, Kadomatsu K, Fan QW, Hagihara M, Senda T, et al. (1998) Female sterility in mice lacking the basigin gene, which encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily. FEBS Lett, 425: 191-194. (Pubitemid 28178887)
9. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ (2003) Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci 44: 1305-1311. (Pubitemid 36297854)
10. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, et al. (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56: 359-367. (Pubitemid 43886799)
11. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, et al. (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158: 1921-1928. (Pubitemid 32545174)
12. Suzuki S, Sato M, Senoo H, Ishikawa K (2004) Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 293: 259-266. (Pubitemid 38083215)
13. Sier CF, Zuidwijk K, Zijlmans HJ, Hanemaaijer R, Mulder-Stapel AA, et al. (2006) EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 118: 2991-2998.
14. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, et al. (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199. (Pubitemid 40524601)
15. Bougatef F, Quemener C, Kellouche S, Naïmi B, Podgorniak MP, et al. (2009) EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 114: 5547-5556.
16. Berditchevski F, Chang S, Bodorova J, Hemler ME (1997) Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3-beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 272: 29174-29180. (Pubitemid 27498208)
17. Coste I, Gauchat JF, Wilson A, Izui S, Jeannin P, et al. (2001) Unavailability of CD147 leads to selective erythrocyte trapping in the spleen. Blood 97: 3984-3988.
18. Yurchenko V, Constant S, Bukrinsky M (2006) Dealing with the family: CD147 interactions with cyclophilins. Immunology 117: 301-309.
19. Belton RJ Jr, Chen L, Mesquita FS, Nowak RA (2008) Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem 283: 17805-17814.
20. Hanna SM, Kirk P, Holt OJ, Puklavec MJ, Brown MH, et al. (2003) A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochem 4: 17.
21. Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, et al. (2009) Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol 391: 518-535.
22. Huang Z, Huang H, Li H, Chen W, Pan C (2009) EMMPRIN expression in tongue squamous cell carcinoma. J Oral Pathol Med 38: 518-523.
23. Liao CG, Kong LM, Song F, Xing JL, Wang LX, et al. (2011) Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion. Mol Cell Biol 31:2591-2604.
24. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, et al. (2012) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46:317-322.
25. Sumida T, Murase R, Onishi-Ishikawa A, McAllister SD, Hamakawa H, et al. (2013) Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. BMC Cancer 22:141.
26. Shang ZJ, Li ZB, Li JR (2006) In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. Int J Oral Maxillofac Surg 35:539-543.
27. Chen B, Chen J, House MG, Cullen KJ, Nephew KP, et al. (2012) Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res10:305-315.
28. Yao J, Liang L, Huang S, Ding J, Tan N, et al. (2010) MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 51:846-856.
29. Kikkawa Y, Sasaki T, Nguyen MT, Nomizu M, Mitak a T, et al. (2007) The LG1-3 tandem of laminin alpha5 harbors the binding sites of Lutheran/basal cell adhesion molecule and alpha3beta1/alpha6beta1 integrins. J Biol Chem 282: 14853-14860. (Pubitemid 47093350)
30. Lu X, Qin W, Li J, Tan N, Pan D, et al. (2005) The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65:6843-6849. (Pubitemid 41060723)
31. Lescaille G, Menashi S, Cavelier-Balloy B, Khayati F, Quemener C, et al. (2012) EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 12: 115.
32. Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, et al. (2007) Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 67: 9-15. (Pubitemid 46142753)
33. Palermo C, Joyce JA (2008) Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29: 22-28
34. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
35. Denaro N, Russi EG, Colantonio I, Adamo V, Merlano MC (2012) The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology 83: 108-116.
36. Tsai WC, Chao YC, Sheu LF, Lin YF, Nieh S, et al. (2007) EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS 115: 929-938. (Pubitemid 47256286)
37. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003) EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20: 161-169. (Pubitemid 36403281)
38. Dang D, Atakilit A, Ramos DM (2008) EMMPRIN modulates migration and deposition of TN-C in oral squamous carcinoma. Anticancer Res 28: 2049-2054.
39. Huang ZQ, Chen WL, Li HG, Li JS, Xu ZY, et al. (2010) Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. J Craniofac Surg 21: 1855-1860.
40. Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22. (Pubitemid 27314632)
41. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34: 122-136.
42. Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, et al. (2011) Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 9: 1.
43. Herszényi L, Farinati F, Cardin R, István G, Molnár LD, et al. (2008) Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinasetype plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8: 194.
44. Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, et al. (2012) ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell 45: 764-776.
45. Beckham TH, Lu P, Cheng JC, Zhao D, Turner LS, et al. (2012) Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int J Cancer 131: 2034-2043.
46. Victor BC, Anbalagan A, Mohamed MM, Sloane BF, Cavallo-Medved D (2011) Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res 13: R115.
47. Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, et al. (2010) Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer 9: 207.